van Staa Tjeerd-Pieter, Cooper Cyrus, Brusse Listy Samuels, Leufkens Hubert, Javaid Muhammad K, Arden Nigel K
Department of Pharmacoepidemiology and Pharmacotherapy, Universtiy of Utrecht, The Netherlands.
Gastroenterology. 2003 Dec;125(6):1591-7. doi: 10.1053/j.gastro.2003.09.027.
BACKGROUND & AIMS: Although patients with inflammatory bowel disease (IBD) have reduced bone mass, there is controversy whether there is an increased risk of fracture. This study examines the risk of fracture and its predictors in patients with IBD.
In a primary care- based nested case-control study, 231,778 fracture cases and 231,778 age- and sex-matched controls were recruited. A history of IBD was assessed from medical records.
The prevalence of IBD was 156 and 282 per 100,000 for Crohn's disease (CD) and ulcerative colitis (UC), respectively. Patients with IBD had an increased risk of vertebral fracture (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.13-2.61) and hip fracture (OR, 1.59; 95% CI, 1.14-2.23). The risk of hip fracture was greater in patients with CD (OR, 1.86; 95% CI, 1.08-3.21) compared with UC (OR, 1.40; 95% CI, 0.92-2.13). Disease severity, assessed by the number of symptoms, predicted fracture even after adjusting for corticosteroid use (OR, 1.46; 95% CI, 1.04-2.04). Only 13% of patients with IBD who had already sustained a fracture were on any form of antifracture treatment.
Patients with IBD have a higher risk of fracture due to both disease activity and use of oral corticosteroids. However, few of these patients are receiving optimal bone-sparing therapy, highlighting the importance of increasing awareness of osteoporosis in those managing these patients.
尽管炎症性肠病(IBD)患者骨量减少,但骨折风险是否增加仍存在争议。本研究探讨IBD患者的骨折风险及其预测因素。
在一项基于初级保健的巢式病例对照研究中,招募了231,778例骨折病例和231,778例年龄及性别匹配的对照。通过病历评估IBD病史。
克罗恩病(CD)和溃疡性结肠炎(UC)的IBD患病率分别为每10万人中156例和282例。IBD患者发生椎体骨折的风险增加(比值比[OR],1.72;95%置信区间[CI],1.13 - 2.61),髋部骨折风险增加(OR,1.59;95% CI,1.14 - 2.23)。与UC患者(OR,1.40;95% CI,0.92 - 2.13)相比,CD患者髋部骨折风险更高(OR,1.86;95% CI,1.08 - 3.21)。即使在调整皮质类固醇使用情况后,通过症状数量评估的疾病严重程度仍可预测骨折(OR,1.46;95% CI,1.04 - 2.04)。在已经发生骨折的IBD患者中,只有13%接受了任何形式的抗骨折治疗。
IBD患者因疾病活动和口服皮质类固醇的使用而具有较高的骨折风险。然而,这些患者中很少有人接受最佳的保骨治疗,这凸显了提高这些患者管理者对骨质疏松症认识的重要性。